National Research (NASDAQ:NRC) Stock Rating Raised to Buy at Wall Street Zen

Posted by George Bondi on Nov 8th, 2026

Wall Street Zen upgraded shares of National Research (NASDAQ:NRC – Free Report) from a hold rating to a buy rating in a research note issued to investors on Saturday,Wall Street Zen reports.

A number of other brokerages have also weighed in on NRC. Citizens Jmp boosted their price objective on shares of National Research from $26.00 to $27.00 and gave the company a “market outperform” rating in a report on Wednesday, October 28th. Weiss Ratings raised National Research from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. Finally, Zacks Research upgraded National Research to a “hold” rating in a research note on Monday, October 5th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, National Research has a consensus rating of “Hold” and a consensus price target of $27.00.

Read Our Latest Report on National Research

National Research Stock Up 1.5%

NASDAQ:NRC opened at $25.86 on Friday. The company has a current ratio of 0.64, a quick ratio of 0.65 and a debt-to-equity ratio of 13.13. National Research has a twelve month low of $11.73 and a twelve month high of $27.41. The company has a market cap of $588.32 million, a PE ratio of 92.36 and a beta of 0.22. The company’s 50 day moving average is $21.55 and its two-hundred day moving average is $19.30.

National Research (NASDAQ:NRC – Get Free Report) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.03. National Research had a net margin of 4.48% and a return on equity of 313.25%. The business had revenue of $38.40 million during the quarter, compared to analysts’ expectations of $35.80 million. Analysts anticipate that National Research will post 0.97 EPS for the current year.

National Research Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 8th. Stockholders of record on Tuesday, December 29th will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Tuesday, December 29th. National Research’s dividend payout ratio is 228.57%.

Institutional Trading of National Research

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Simplex Trading LLC increased its position in National Research by 556.4% during the third quarter. Simplex Trading LLC now owns 3,282 shares of the company’s stock worth $70,000 after purchasing an additional 2,782 shares during the last quarter. Bank of America Corp DE raised its stake in National Research by 3.0% during the first quarter. Bank of America Corp DE now owns 112,468 shares of the company’s stock worth $1,910,000 after purchasing an additional 3,323 shares during the period. Bank of New York Mellon Corp raised its stake in National Research by 4.0% during the first quarter. Bank of New York Mellon Corp now owns 250,707 shares of the company’s stock worth $4,257,000 after purchasing an additional 9,730 shares during the period. Hsbc Holdings PLC purchased a new position in National Research during the first quarter worth about $180,000. Finally, Empowered Funds LLC acquired a new position in National Research in the 1st quarter valued at about $226,000. Institutional investors and hedge funds own 47.26% of the company’s stock.

About National Research

(Get Free Report)

National Research Corporation, formerly traded on the Nasdaq under the symbol NRC, provides research, analytics and performance-improvement services to the health care industry. Through its NRC Health business, the company helps hospitals, health systems and other care organizations understand and improve patient, consumer and employee experiences.

Its offerings have included patient and employee surveys, market research, reputation management, loyalty and engagement programs, benchmarking, and software tools that turn feedback and other data into operational insights.